PMH4: THE BUDGET IMPACT PHARMACOTHERAPY SELECTION FOR MAJOR DEPRESSIVE DISORDER: A MULTINATIONAL STUDY  by Casciano, JP et al.
32 Abstracts
OBJECTIVE: The objective of this study was to docu-
ment the clinical and economic characteristics of ambula-
tory family medicine patients receiving antidepressant
medications.
METHODS: The medication profiles of the electronic
medical records (EMR) of all Family Medicine patients at
the Medical College of Georgia were evaluated. Only pa-
tients prescribed an antidepressant drug within the previ-
ous 6 months were reviewed. Patient records were re-
viewed in the order in which they were entered into the
EMR system.
RESULTS: The electronic records of 116 patients were
reviewed by the same physician researcher. Demographic
and clinical data for 89 (76.7%) female and 27 (23.3%)
male patients were evaluated. The mean age for these pa-
tients was 46.5 years. Sixty-two (53.4%) patients were
white, 38 (32.8%) were black. Although usually consid-
ered risk factors for the development of depression, mari-
tal status and the use of alcohol were not noted in 47
(40.5%) and 62 (53.4%) patients, respectively. The most
common comorbid conditions were hypertension (47.4%),
gastroesophageal reflux disease (GERD) (20.7%), arthritis
(20.7%), anxiety (18.1%), diabetes mellitus (17.2%), and
pain syndromes (45.7%). Thirty-one (26.7%) patients, re-
ceived amitriptyline. Twenty-two (71%) received less than
50 mg per day. Fourteen (12%) patients received two an-
tidepressants, most often an SSRI in the morning with a
sedating agent at bedtime. Of the 26 patients with avail-
able financial data, 25 patients paid a co-payment of $5.00
or less. 
CONCLUSIONS: Antidepressant drugs are frequently
prescribed in primary care patients with multiple comor-
bid conditions (mean 3.9).
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OBJECTIVE: The objective of this study was to examine
the cost-effectiveness of fluvoxamine compared to treat-
ment with tricyclic antidepressants (TCAs) in patients
who suffer depressive episodes.
METHODS: The setting for this study was France. A
Markov process model was constructed to model the ef-
fectiveness, as measured by time without depression, and
the costs of both treatments. The model examined a pe-
riod of 18 months in order to capture the influence of
both relapses and recurrences on the outcomes. Data for
the construction of the model came from the published
literature, an expert panel, and a large multicenter ran-
domized clinical trial. Costs were obtained from pub-
lished sources.
RESULTS: The results of the baseline analysis showed
that the use of fluvoxamine in the maintenance treatment
(recurrence prevention) of depressive disorders was less
costly than TCAs with total costs (direct and indirect
costs) of 40,232.40 FF versus 52,257.53 FF, respectively.
In addition, due to the prevention of relapse and recur-
rence, effectiveness fluvoxamine was favored, as it was
associated with a longer period of time without depres-
sion when compared to therapy with TCAs: 79% of the
study period compared to 71% for TCAs. Sensitivity
analyses confirmed the robustness of these findings.
CONCLUSION: In conclusion, based on the assump-
tions used in the model, the use of fluovoxamine as main-
tenance therapy is clinically and economically justified in
patients with depressive disorders.
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OBJECTIVE: We conducted a multinational pharmaco-
economic evaluation of treatment for major depressive
disorder (MDD) to assess the potential budget impact of
changes in antidepressant prescribing patterns in Canada,
Germany, Italy, the Netherlands, Poland, Spain, Sweden,
Switzerland, the United Kingdom, the United States, and
Venezuela. 
METHODS: The analysis compared the serotonin-nore-
pinephrine reuptake-inhibitor (SNRI), extended-release
venlafaxine, to selective serotonin reuptake-inhibitors
(SSRIs) and tricyclic antidepressants (TCAs). A meta-
analysis was performed to determine the clinical rates of
success, defined as a 50% reduction in depression scores
on the Hamilton Depression Scale (HAM-D) or the
Montgomery-Asberg Depression Rating Scale (MADRS).
Treatment regimen costs were determined from standard
lists, fee schedules, and communication with local health
economists in each country. We included data from 48
studies on 4,690 patients in the meta-analysis. The meta-
analytic rates were applied to decision analytic models to
calculate expected cost and expected outcomes for each
comparator. Cost-effectiveness was determined using ex-
pected values for both a successful outcome (as defined
by the meta-analysis), and a composite measure of out-
come termed “Symptom-Free Days.” A policy analysis
was conducted to examine the budgetary impact on the
health system, in each country, of increasing the utiliza-
tion of the most effective comparator.
RESULTS: Treatment of MDD with extended-release
venlafaxine yielded the highest overall efficacy rates for
outpatients (73.7%) and inpatients (62.3%). Extended-
release venlafaxine had the highest failure rate due to lack
of efficacy (5.3%) and adverse drug reactions (11.3%).
Initiating treatment of MDD with extended-release ven-
lafaxine yielded the lowest expected cost for outpatients
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in 9 of the 11 countries studied, and for inpatients in 10
of the 11 countries studied. The weighted average ex-
pected cost per patient for MDD treatment varied from
US $642 (Poland) to US $5,825 (US). The estimated bud-
getary impact to the primary payer for each 1% of utili-
zation of extended-release venlafaxine ranged from US
$61,640 (Switzerland) to US $1,565,900 (Germany) for
each 1 million population. 
CONCLUSIONS: Policy-makers should implement mea-
sures to increase the utilization of cost-effective antide-
pressant treatment such as extended-release venlafaxine.
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OBJECTIVE: To assess the relationship between illness
severity and costs of care in noninstitutionalized patients
with Alzheimer’s Disease in the United Kingdom.
METHODS: In this cross-sectional, multicenter analysis,
Alzheimer’s Disease patients cared for in the community
(128), their caregivers (128), and 56 matched controls
were recruited chronologically and interviewed once to
establish resource use over the previous 3 months. Pa-
tients were stratified into three severity groups according
to their cognitive function as assessed by their Mini Men-
tal State Exam score. Costs were calculated from the per-
spective of society as a whole.
RESULTS: Over the 3-month period, total mean cost per
control subject (£387) was minor compared with the
mean cost incurred by patients with mild (£6,616), mod-
erate (£10,250), and severe (£13,593) Alzheimer’s Dis-
ease. Indirect cost, mainly time spent by caregivers, was
the main cost component in all groups (68.6%), followed
by direct medical costs (24.7%).
CONCLUSION: The cost of care for an Alzheimer’s Dis-
ease patient is substantial and is directly related to the se-
verity of the patient’s illness.
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OBJECTIVE: To develop a health-related quality of life
questionnaire to measure the effects of treatment on the
quality of life of people with schizophrenia, the Schizo-
phrenia Quality of Life Scale (SQLS).
METHODS: A standardized state-of-the-art methodol-
ogy has been used for the development of the SQLS.
Items were generated from in-depth interviews with 20
patients and eight health professionals. From a list of 440
statements, a pilot questionnaire containing 80 items was
developed by a panel of experts. The pilot questionnaire
was tested on 20 patients, which resulted in some word-
ing changes. A sample of 161 patients completed the 80-
item questionnaire. A factor analysis using Varimax rota-
tion was then conducted. This identified 31 questions
tapping three factors: psychological, motivational, and
physical symptoms. The psychometric properties of the
SQLS were then assessed using the following methodol-
ogy. Sixty-five patients were given the SQLS to complete,
along with the following measures: the SF-36, the Hospi-
tal Anxiety and Depression Scale (HADS), and the Gen-
eral Health Questionnaire (GHQ-12). A clinical assess-
ment using the Clinical Global Impressions and the
Health of the Nation Outcome Scales (HONOS) was
made by a psychiatrist. A subset of the patients was asked
to complete the SQLS for a second time to assess the re-
producibility of the measure.
RESULTS: The validity and reliability of the scale are
good. 
CONCLUSIONS: The SQLS is now available for use, al-
though further studies of its psychometric properties are
ongoing.
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With the increase of QoL assessment in clinical trials, it is
necessary to have cross-culturally valid instruments to
make comparisons of health status outcomes and pool
data across countries. The IIEF is a 15-item instrument
designed in English to assess erectile dysfunction. Prior to
use in an international trial, it underwent cross-cultural
adaptation in 31 languages. This involved the recruitment
of a QoL specialist in each target country. Two indepen-
dent forward translations were produced by native speak-
ers, bilingual in English. These were reconciled and back-
translated into English. The translations were tested for
comprehension in a sample target population, compared
and internationally harmonized. The developer clarified
concepts underlying each item. Translation was difficult,
especially when selecting equivalent response categories
and appropriate equivalents of common English struc-
tures and expressions. The difficulty of the translation
and its acceptability depended on the comparability of
the original and the target language and culture. Because
English is flexible, it was possible to accept “Most of the
times (much more than half of the time)” as an answer to
the question: “How often have you felt sexual desire in
